Publications

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Marroquin RM, Cannova JM, Žucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Requena GA, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E, PRISM-AML Investigators. Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 42507967

Lyubchenko T, Berdyshev E, Weight RM, Xiao O, Shah NJ, Markova A, Lacouture ME, Kern JA, Goleva E, Leung DYM. Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients. Allergy. 2026. PMID: 42500847

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Nowecki Z, Tolaney SM, Zhao K, Atuah K, Verma D, Xu B, Bardia A, TROPION-Breast01 investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study. ESMO open. 2026. PMID: 42497483

Rugo HS. Response to correspondence received on "New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice". Breast (Edinburgh, Scotland). 2026. PMID: 42509147

Williams CL, Yang A, Gilmore S, Stanfield D, Steiding P, Atreya CE, Piawah S. "Doing My Part in My Healing": A Qualitative Study Exploring Integrative Oncology Practices Among African Americans with Cancer. Global advances in integrative medicine and health. 2026. PMID: 42495180

Nguyen DH, Bruck M, Rosenbluth JM. A Shape Analysis Algorithm Quantifies Spatial Morphology and Context of 2D to 3D Cell Culture for Novel Quantitation of Phenotypes. Journal of visualized experiments : JoVE. 2026. PMID: 42574504

Balas J, Bowling L, Shakhnazaryan N, Aggarwal RR, Borno HT, Hong JC, Huang FW, Tong B, Kwon DH. Evaluation of an Artificial Intelligence Communication Platform for Racial Biases in Pretest Education About Prostate Cancer Germline Testing. JCO clinical cancer informatics. 2026. PMID: 42475635

Trivedi A, Miyazawa B, Fields AT, Matthews M, Vivona L, Keane C, Potter D, Geng H, Zhang H, Taenaka H, Kwek SS, Herrera-Rodriguez K, Nunez-Garcia B, de Menezes EM, Barry M, Nair A, Kuhn B, Norris PJ, Fong L, Fitzpatrick MM, Schreiber M, Kornblith LZ, Pati S. Lyophilized platelet derived extracellular vesicles promote hemostasis and attenuate intracranial hemorrhage following traumatic brain injury. Journal of translational medicine. 2026. PMID: 42472813

Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, Face C, Chaudhry S, Idossa D, Poonacha T, Huppert L, Quintal L, Melisko M, Majure M, Tsai K, Kordic A, Chien J, Mortimer J, Rugo HS, Lechner MG, Blaes A, McCann KE. Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer. Clinical breast cancer. 2026. PMID: 42607491

Grinda T, Heiling HM, Tayob N, Smith KL, Davis R, Cotter C, DeMeo MK, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Isaacs C, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Mayer EL, Tolaney SM, Rimawi MF, Ruddy KJ, Rocque G, Krop IE, Lin NU, Freedman RA. Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. Breast (Edinburgh, Scotland). 2026. PMID: 42501479

Krasnow NA, Salans M, Jayaraj M, Kuwahara K, Zhou MH, Boreta L, Braunstein SE, Aghi MK, Chien J, Rugo H, Melisko ME, Morshed RA, Vasudevan HN, Huppert LA. Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment. 2026. PMID: 42474755

Thati N, Trudeau J, Ng DQ, Chavez-Iglesias E, Dhruva A, Olshen A, Chan R, Chan A, Kober KM. Perturbed Inflammatory, Proliferation, Regulatory, And Neurodegeneration Signaling Pathways Are Associated With Trait Anxiety In Cancer Survivors. Research square. 2026. PMID: 42523461

Topp MS, Shah BD, Jabbour E, Park JH, Shaughnessy P, Logan AC, Sandhu KS, Abedi M, Bishop MR, DeAngelo DJ, Yin X, Davi R, Hodby K, Malladi R, Brugger W, Shang J, Roddie C, Kantarjian HM. Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42469475

Amouzegar A, Shaw R, Tsai KK, Olson D, Gibney GT. Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2026. PMID: 42462189

Ho LS, Alsultan A, Smits MLJ, Koopman M, Bruijnen R, Braat AJAT, Fowers KD, Dreher MR, Bol GM, Lam MGEH. Phase I Dose-Escalation Study Combining Irinotecan-Loaded Drug-Eluting Bead Chemoembolization with Yttrium-90 Glass Microspheres Radioembolization in Colorectal Liver Metastases (DEBIR90Y). Journal of vascular and interventional radiology : JVIR. 2026. PMID: 42462844

Rimner A, Lebow ES, Fitzgerald KJ, Kratochvil L, Toumbacaris N, Gelblum DY, Kotecha R, Gomez DR, Wu AJ, Shepherd AF, Yorke ED, Eng J, Ng K, Riely GJ, Iqbal A, Rudin CM, Jones DR, Isbell JM, Rocco G, Rusch VW, Ginsberg MS, Zhang Z, Simone CB, Kris MG, Shaverdian N, Chaft JE. Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 42462186

Li C, Venkatesh H, Trieu L, Fong L. Strategic engineering B cell immunity for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society. 2026. PMID: 42456977

Cho B, Usman L, Lomax Truong T, Phelan D, Datta D, Aras MA, Hetts S, Ohliger M, Conrad M, Ge J. Incidence and diagnostic yield of repeat imaging-based screening for hepatic arteriovenous malformations in patients with HHT. Hepatology communications. 2026. PMID: 42486800

Moore CG, Chyong DI, Daver N, Aubrey BJ, Marx KR, Takahashi K, Abaza Y, Smith CC, Amrein PC, Hock H, Hobbs G, Narayan R, Lee MH, Moran JA, Bergeron M, Foster JE, Perl AE, Levis MJ, DiNardo CD, Brunner AM, Fathi AT. Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia. British journal of haematology. 2026. PMID: 42438311

Keane G, Lam MGEH, Smits MLJ, Bol GM, de Jong HWAM, Bruijnen RCG, Braat AJAT. A novel approach to radioembolization treatment planning using a hybrid [99mTc]Tc-MAA contrast enhanced SPECT/CT. European journal of nuclear medicine and molecular imaging. 2026. PMID: 42435201